Probability, uncertainty, and prostate cancer

Annals of Internal Medicine

Volumn 158, Issue 3, 2013, Pages 211-212

  Concato, John ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL PRACTICE; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; LONGEVITY; PATIENT CARE; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84873389624     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-3-201302050-00012     Document Type: Editorial

References (12)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. [PMID: 22237781]
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-61. [PMID: 1707140]
3. Barry MJ. The PSA conundrum [Editorial]. Arch Intern Med. 2006;166:7-8. [PMID: 16401804]
4. Concato J. What will the emperor say? Screening for prostate cancer as of 2008. Cancer J. 2009;15:7-12. [PMID: 19197166]
5. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. [PMID: 19297565]
6. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al.; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32. [PMID: 22228146]
7. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. [PMID: 19297566]
8. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90. [PMID: 22417251]
9. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372:2152-61. [PMID: 19101391]
10. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies. Model estimates of potential benefits and harms. Ann Intern Med. 2013;158:145-53.
11. Concato J. Is it time for medicine-based evidence? [Editorial]. JAMA. 2012;307:1641-3. [PMID: 22511693]
12. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94:167-73. [PMID: 11830606]